IPO Profile

Adeza Biomedical
1240 Elko Drive, Sunnyvale, CA 94089
Tel: 408-745-0975
Web: https://www.adeza.com
Ticker: ADZA
Amount Raised: $60,000,000.00

Description:
We design, develop, manufacture and market innovative products for women�s health. Our initial focus is on reproductive healthcare, using our proprietary technologies to predict preterm birth and assess infertility. Our principal product is a patented diagnostic test, the Fetal Fibronectin Test, that utilizes a single-use, disposable cassette and is analyzed on our patented instrument, the TLiIQ System. This product is approved by the Food and Drug Administration, or FDA, for broad use in assessing the risk of preterm birth. Our Fetal Fibronectin Test is designed to objectively determine a woman�s risk of preterm birth by detecting the presence of a specific protein, fetal fibronectin, in vaginal secretions during pregnancy. Testing for fetal fibronectin during pregnancy provides a more accurate assessment of the likelihood of a preterm birth than traditional methods. Preterm births have historically accounted for up to 85% of all pregnancy-related complications and deaths in the United States, and over $13 billion in costs were associated with the care of preterm or low birth weight infants in 2001. By correctly identifying women at risk for preterm birth, we believe our Fetal Fibronectin Test leads to improved patient care and significant cost savings and has the potential to fundamentally change how healthcare providers select the appropriate course of treatment for pregnant women.